Dermapharm Holding
DMP.DE Mid CapHealthcare · Drug Manufacturers - Specialty & Generic
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Dermapharm Holding en bref
Dermapharm Holding (DMP.DE) is currently trading at 47,50 € with a market capitalization of 2,1 Md €. The trailing P/E ratio stands at 17.72x, with a forward P/E of 16.23x. The 52-week range spans from 31,70 € to 51,90 €; the current price is 8.5% below the yearly high. Year-over-year revenue growth stands at +1.3%. The net profit margin stands at 12.2%.
💰 Dividende
Dermapharm Holding currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
4 analystes évaluent Dermapharm Holding (DMP.DE) au consensus : Acheter. L'objectif de cours moyen est de 50,38 €, soit un potentiel de +6.05% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 44,00 € à 60,00 €.
Dermapharm Holding : la thèse d'investissement en détail
Dermapharm Holding (DMP.DE) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in Germany. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Earnings growth of 35.5% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 65.49%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
Le scénario baissier
Revenue growth has slowed to just 1.3%, which is below nominal GDP — the business is no longer outgrowing the broader economy.
Thèse d'investissement : forces et faiblesses
- Rentabilité élevée des capitaux propres (20.8% ROE)
- Marge brute élevée de 65.49% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- Free cash flow positif
Aucun signal d'alerte significatif dans les indicateurs actuels.
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to relatively defensive market behavior, higher leverage relative to equity.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Dermapharm Holding?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
